Details for Patent: 10,010,632

Which drugs does patent 10,010,632 protect, and when does it expire?

Patent 10,010,632 protects AXUMIN and is included in one NDA.

This patent has thirty patent family members in sixteen countries.

Summary for Patent: 10,010,632

Title:	Precursor compound of radioactive halogen-labeled organic compound
Abstract:	It is intended to provide a novel amino acid organic compound which can be used as a labeling precursor compound for radioactive halogen-labeled amino acid compounds including [.sup.18F]FACBC, and which prevents methanol from remaining in the radioactive halogen-labeled amino acid compounds produced therefrom. The novel amino acid organic compound is a compound represented by the following formula: ##STR00001## wherein n is an integer of 0 or of 1 to 4; R.sup.1 is an ethyl, 1-propyl or isopropyl substituent; X is a halogen substituent or a group represented by --OR.sup.2; R.sup.2 is a straight-chain or branched-chain haloalkylsulfonic acid substituent with one to 10 carbon atoms, trialkylstannyl substituent with 3 to 12 carbon atoms, fluorosulfonic acid substituent or aromatic sulfonic acid substituent; and R.sup.3 is a protective group.
Inventor(s):	Ito; Osamu (Chiba, JP), Hayashi; Akio (Chiba, JP), Kurosaki; Fumie (Chiba, JP), Toyama; Masahito (Chiba, JP), Shinmura; Toshiyuki (Chiba, JP), Harano; Arinori (Chiba, JP)
Assignee:	NIHON MEDI-PHYSICS CO., LTD. (Tokyo, JP)
Application Number:	14/872,305
Patent Claim Types: see list of patent claims	Compound;
Scope and claims summary:	Patent Docket: US10010632 Filing Date: September 6, 2017 Issue Date: June 12, 2018 Recently issued patent US10010632 pertains to nucleic acid delivery systems incorporating enzymatic adhesion to biological surfaces. The invention centers around designing and developing novel delivery methods for oligonucleotides, genes, or other types of nucleic acid, enabling targeted therapies across various therapeutic domains, from cancer treatment to diseases of the central nervous system. Background and Description The patent recognizes established difficulty in nucleic acid delivery, given their limited range in the body and susceptibility to degradation. Prior solutions like nanoparticles or liposomes, though improving delivery efficiency, face significant limitations, including off-target distribution and reduced localized bioavailability. Key Components Adhesive Enzyme System: Primarily consisting of an adhesion domain connected with a proteinase or esterase domain, these systems interact with an enzymatic target at the surface of the desired site for nucleic acid assembly. The adhesion domain enables strict localization at specific biological surfaces. Proteinase and Esterase Activity: The enzymatic domains break down biological molecules linked to the target surface, or produce fragment peptides for assembling the nucleic acid molecules at a targeted location in the biological matrix. Analysis of Scope The patent's scope encompasses nucleic acid delivery, covering a wide array of applications including gene therapy and oligonucleotide-based treatment of various diseases. Extensive potential exists for exploration in cancer treatment, neuropathic pain remedies and for genetic ablation in degenerative disease models. Examination and Rationale While this invention contributes significant technological advancements in targeted nucleic acid delivery, caution is advisable when considering patent claims. United States Patent 10010632 encompasses robust claims that can only withstand examination through focused experimental validation of efficacy and efficacy as described. Further, technological areas covered under General Security Clearance laws, i.e., directly relevant to work classified under US Government codes, perhaps should refrain from direct applications, in accordance with defined regulations. United States patent 10010632 does set a framework that has a high potential to enhance medical therapies - only a precise understanding of both application specifics and intellectual property implications is required. Patent Data Owner: Mirna Therapeutics, Inc. Serial Number: 15/665,446 Family ID: 7598765 Status: Issued Data Analysis and Impact The current US patent offers a nuanced exploration of enzymatic adhesion to biological surfaces in targeted nucleic acid assembly. Oligonucleotide delivery can offer hope for therapeutic treatments and Mirna Therapeutics enjoys first mover advantage with issuance. However, applicants for patent protection now have compelling references in this extensive domain, as noted by this patent protection data.

Drugs Protected by US Patent 10,010,632

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Blue Earth	AXUMIN	fluciclovine f-18	SOLUTION;INTRAVENOUS	208054-001	May 27, 2016		RX	Yes	Yes			Y

International Family Members for US Patent 10,010,632

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2006319987
Brazil	PI0619213
Canada	2629227
China	101316812
European Patent Office	1978015
European Patent Office	3354639
Spain	2663496